Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares
April 12 2022 - 10:02PM
Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a
clinical-stage immuno-oncology company committed to giving patients
back their innate ability to fight cancer, today announced the
pricing of its previously announced public offering of 22,500,000
of its common shares at a public offering price of $4.00 per common
share. In addition, Affimed has granted the underwriters a 30-day
over-allotment option to purchase up to 3,375,000 common shares at
the public offering price less underwriting discounts. After
deducting the underwriting discounts, the net proceeds of the
public offering are expected to be $84.6 million. The offering is
expected to close on or about April 18, 2022, subject to customary
closing conditions.
Jefferies LLC, SVB Leerink, Truist Securities,
Inc. and Wells Fargo Securities, LLC are acting as joint
book-running managers and Berenberg Capital Markets LLC is acting
as a co-manager of the offering. A shelf registration statement
relating to these securities filed with the Securities and Exchange
Commission (the “SEC”) was declared effective by the SEC on April
6, 2022. The offering will be made only by means of a prospectus
and prospectus supplement. A preliminary prospectus supplement and
accompanying prospectus related to the offering have been filed
with the SEC and are available at the SEC’s website located at
www.sec.gov. A final prospectus supplement and accompanying
prospectus will be filed with the SEC. Copies of the preliminary
prospectus supplement and accompanying prospectus related to the
offering may be obtained by contacting Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, or by telephone at (877) 821-7388 or by
email at Prospectus_Department@Jefferies.com, SVB Securities LLC,
Attn: Syndicate Department, 53 State Street, 40th Floor, Boston,
Massachusetts 02109, by telephone at 1-800-808-7525, ext. 6105, or
by email at syndicate@svbleerink.com, Truist Securities, Inc.,
Attention: Prospectus Department, 3333 Peachtree Road, NE, 11th
Floor, Atlanta, Georgia 30326, by telephone at (800) 685-4786, or
by email at TruistSecurities.prospectus@Truist.com, or Wells Fargo
Securities, LLC, Attention: Equity Syndicate Department, 500 West
33rd Street, New York, New York 10001, by telephone at (833)
690-2713, or by email at cmclientsupport@wellsfargo.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer by actualizing the untapped
potential of the innate immune system. The Company’s proprietary
ROCK® platform enables a tumor-targeted approach to recognize
and kill a range of hematologic and solid tumors, enabling a broad
pipeline of wholly-owned and partnered single agent and combination
therapy programs. The ROCK® platform predictably generates
customized innate cell engager (ICE®) molecules, which use
patients’ immune cells to destroy tumor cells. This innovative
approach enabled Affimed to become the first company with a
clinical-stage ICE®. Headquartered in Heidelberg, Germany, with
offices in New York, NY, Affimed is led by an experienced team of
biotechnology and pharmaceutical leaders united by a bold vision to
stop cancer from ever derailing patients’ lives.
Forward-looking Statements
This press release contains statements that
constitute “forward-looking statements,” including with respect to
the proposed offering of common shares and the anticipated use of
the net proceeds. No assurance can be given that the offering
discussed above will be completed on the terms described, or at
all, or that the net proceeds of the offering will be used as
indicated. Forward-looking statements are subject to numerous
conditions, many of which are beyond the control of the company,
including those set forth in the Risk Factors section of the
company’s registration statement and preliminary prospectus for the
company’s offering filed with the Securities and Exchange
Commission (“SEC”). Copies are available on the SEC’s website,
www.sec.gov. Given these risks, uncertainties, and other factors,
you should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these
forward-looking statements, even if new information becomes
available in the future.
Affimed Investor and Media
Contact:Alexander FudukidisDirector, Head of Investor
RelationsE-Mail: a.fudukidis@affimed.com, IR@affimed.comTel.: +1
(917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024